EBITDA Margin % is calculated as EBITDA divided by its Revenue. Kerala Ayurveda's EBITDA for the
three
months ended in Mar. 2026 was ₹-52 Mil. Kerala Ayurveda's Revenue for the
three
months ended in Mar. 2026 was ₹347 Mil. Therefore, Kerala Ayurveda's EBITDA margin for the quarter that ended in Mar. 2026 was -14.95%.
Kerala Ayurveda (BOM:530163) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Kerala Ayurveda EBITDA Margin % Related Terms
Kerala Ayurveda EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Kerala Ayurveda's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530163 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kerala Ayurveda's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kerala Ayurveda EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kerala Ayurveda's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Kerala Ayurveda's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kerala Ayurveda (BOM:530163) has a EBITDA Margin % of -14.95% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kerala Ayurveda and its competitors. According to the industry distribution chart, Kerala Ayurveda ranks #743 out of 952 companies in the Drug Manufacturers industry, placing it in the top 78%.
Is Kerala Ayurveda's EBITDA Margin % too high?
Kerala Ayurveda's current EBITDA Margin % is -14.95%. Based on the distribution chart, Kerala Ayurveda ranks #743 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kerala Ayurveda has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Kerala Ayurveda's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kerala Ayurveda ranks #743 out of 952 companies for EBITDA Margin %. This places Kerala Ayurveda in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Kerala Ayurveda and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kerala Ayurveda's current EBITDA Margin % is -14.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kerala Ayurveda stock overvalued right now?
Based on GuruFocus' analysis, Kerala Ayurveda (BOM:530163) is currently considered Possible Value Trap. The stock's GF Value™ is ₹318.38, compared to a current price of ₹187.10 — trading 41.2% below its estimated fair value. The current EBITDA Margin % is -14.95%. Kerala Ayurveda's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Kerala Ayurveda (BOM:530163), the current EBITDA Margin % is -14.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kerala Ayurveda (BOM:530163) Overvalued in 2026?
Based on GuruFocus' analysis, Kerala Ayurveda stock appears to be undervalued.
The current stock price of ₹187.10 is trading 41.2% below its estimated GF Value™ of ₹318.38.
GuruFocus considers Kerala Ayurveda to be Possible Value Trap.
Key valuation signals for BOM:530163:
EBITDA Margin %: -14.95%
GF Value™: ₹318.38 vs. price of ₹187.10 (41.2% below fair value)
No single metric tells the full story. See the BOM:530163 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kerala Ayurveda Ltd is engaged in producing and selling ayurvedic products and providing healthcare services. The company offers ayurvedic medicine products for diabetes and heart health, skin and hair care, kids' health, women's care, men's care, gastro care, respiratory and allergy, general healthcare, massage oils, renal care, and joint care. It provides services through wellness clinics, resorts, hospitals, and academies. The company has only one reportable business segment, i.e., Full-spectrum Ayurvedic wellness. It generates maximum revenue from the sale of products. Geographically, the company generates maximum revenue from its business in India and also has some exposure to other markets.
47GF Score
Get the complete analysis for BOM:530163
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530163 has been successfully added to your 
